Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study

dc.contributor.authorMayén, Ana Lucía
dc.contributor.authorSabra, Mirna
dc.contributor.authorAglago, Elom K.
dc.contributor.authorPerlemuter, Gabriel
dc.contributor.authorVoican, Cosmin
dc.contributor.authorRamos, Inés
dc.contributor.authorDebras, Charlotte
dc.contributor.authorBlanco, Jessica
dc.contributor.authorViallon, Vivian
dc.contributor.authorFerrari, Pietro
dc.contributor.authorOlsen, Anja
dc.contributor.authorTjønneland, Anne
dc.contributor.authorLangmann, Fie
dc.contributor.authorDahm, Christina C.
dc.contributor.authorRothwell, Joseph A.
dc.contributor.authorLaouali, Nasser
dc.contributor.authorMarques, Chloé
dc.contributor.authorSchulze, Matthias B.
dc.contributor.authorKatzke, Verena
dc.contributor.authorKaaks, Rudolf
dc.contributor.authorPalli, Domenico
dc.contributor.authorMacciotta, Alessandra
dc.contributor.authorPanico, Salvatore
dc.contributor.authorTumino, Rosario
dc.contributor.authorAgnoli, Claudia
dc.contributor.authorFarràs, Marta
dc.contributor.authorMolina Montes, Esther
dc.contributor.authorAmiano, Pilar
dc.contributor.authorChirlaque, María Dolores
dc.contributor.authorCastilla, Jesús
dc.contributor.authorWerner, Mårten
dc.contributor.authorBodén, Stina
dc.contributor.authorHeath, Alicia K.
dc.contributor.authorTsilidis, Kostas
dc.contributor.authorAune, Dagfinn
dc.contributor.authorWeiderpass, Elisabete
dc.contributor.authorFreisling, Heinz
dc.contributor.authorGunter, Marc J.
dc.contributor.authorJenab, Mazda
dc.date.accessioned2024-07-05T11:49:19Z
dc.date.available2024-07-05T11:49:19Z
dc.date.issued2024-06-03
dc.date.updated2024-06-28T08:49:15Z
dc.description.abstractBackground Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) are implicated in the aetiology of non-communicable diseases. Our study aimed to evaluate associations between NAFLD and MetS with overall and cause-specific mortality. Methods We used dietary, lifestyle, anthropometric and metabolic biomarker data from a random subsample of 15,784 EPIC cohort participants. NAFLD was assessed using the fatty liver index (FLI) and MetS using the revised definition. Indices for metabolic dysfunction-associated fatty liver disease (MAFLD) were calculated. The individual associations of these indices with overall and cause-specific mortality were assessed using multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (95%CIs). As a subobjective, risk associations with adaptations of new classifications of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic and alcohol-related liver disease (MetALD) were also assessed. Results Among the 15,784 sub-cohort participants, a total of 1997 deaths occurred (835 due to cancer, 520 to CVD, 642 to other causes) over a median 15.6 (IQR, 12.3-17.1) years of follow-up. Compared to an FLI < 30, FLI >= 60 was associated with increased risks of overall mortality (HR = 1.44, 95%CI = 1.27-1.63), and deaths from cancer (HR = 1.32, 95%CI = 1.09-1.60), CVD (HR = 2.06, 95% CI = 1.61-2.63) or other causes (HR = 1.21, 95%CI = 0.97-1.51). Mortality risk associations were also elevated for individuals with MAFLD compared to those without. Individuals with MetS were at increased risk of all mortality endpoints, except cancer-specific mortality. MASLD and MetALD were associated with higher risk of overall mortality. Conclusions Our findings based on a prospective cohort suggest that individuals with hepatic steatosis or metabolic dysfunction have a higher overall and cause-specific mortality risk.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1741-7015
dc.identifier.pmid38825687
dc.identifier.urihttps://hdl.handle.net/2445/214368
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12916-024-03366-3
dc.relation.ispartofBMC Medicine, 2024, vol. 22, num. 1
dc.relation.urihttps://doi.org/10.1186/s12916-024-03366-3
dc.rightscc by (c) Mayén, Ana Lucía et al, 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationMalalties del fetge
dc.subject.classificationSíndrome metabòlica
dc.subject.otherLiver diseases
dc.subject.otherMetabolic syndrome
dc.titleHepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
s12916-024-03366-3.pdf
Mida:
814.5 KB
Format:
Adobe Portable Document Format